• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Zymeworks Inc. - Common Stock (NQ:ZYME)

    11.43 +0.08 (+0.70%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 504,343
    Open 11.23
    Bid (Size) 11.00 (2)
    Ask (Size) 12.50 (2)
    Prev. Close 11.35
    Today's Range 11.02 - 11.72
    52wk Range 8.210 - 17.70
    Shares Outstanding 57,771,204
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge
    Zymeworks is entitled to receive a $20 million milestone payment in connection with the NMPA approval of zanidatamab as part of its agreement with BeOne Medicines. 
    Via Stocktwits
    Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
    From Zymeworks Inc.
    Via GlobeNewswire

    Performance

    YTD
    -22.7%
    -22.7%
    1 Month
    -11.3%
    -11.3%
    3 Month
    -18.1%
    -18.1%
    6 Month
    -19.5%
    -19.5%
    1 Year
    +31.2%
    +31.2%

    More News

    Read More
    Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    Earnings Scheduled For May 8, 2025
    Via Benzinga
    Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)
    Via Benzinga
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy
    Via Stocktwits
    Exposures Product Safety
    Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
    From Zymeworks Inc.
    Via GlobeNewswire
    Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
    Via Benzinga
    Topics Earnings
    Exposures Financial
    Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 5, 2025
    Via Benzinga
    Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Zymeworks in Focus for Insider Activity: Catalysts Ahead
    Via MarketBeat
    Exposures Product Safety
    Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
    From Zymeworks Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Zymeworks Inc. - Common Stock publicly traded?
    Yes, Zymeworks Inc. - Common Stock is publicly traded.
    What exchange does Zymeworks Inc. - Common Stock trade on?
    Zymeworks Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Zymeworks Inc. - Common Stock?
    The ticker symbol for Zymeworks Inc. - Common Stock is ZYME on the Nasdaq Stock Market
    What is the current price of Zymeworks Inc. - Common Stock?
    The current price of Zymeworks Inc. - Common Stock is 11.43
    When was Zymeworks Inc. - Common Stock last traded?
    The last trade of Zymeworks Inc. - Common Stock was at 05/30/25 04:00 PM ET
    What is the market capitalization of Zymeworks Inc. - Common Stock?
    The market capitalization of Zymeworks Inc. - Common Stock is 660.32M
    How many shares of Zymeworks Inc. - Common Stock are outstanding?
    Zymeworks Inc. - Common Stock has 660M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.